SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : E*Trade (NYSE:ET) -- Ignore unavailable to you. Want to Upgrade?


To: Scott Stents who wrote (3453)8/3/1998 4:31:00 PM
From: Oeconomicus  Respond to of 13953
 
Scott, while that is generally true, EGRP did not issue "an infinite amount of shares". Of course, they do have to deploy that added capital in a way that will produce good long-term returns and that is by no means certain, but it seems like a reasonable supposition. Anyway, price-to-book is an accepted metric for valuing financial services businesses and, in any industry, a low ratio tends to provide support.

BTW, anyone still getting Professional Edge? Has Keith Benjamin publish new long-range projections for EGRP yet, or did he just revise 1999? I'd be interested in what he or any other analyst is saying about the outlook for profit growth *beyond* the near-term marketing push.

Bob



To: Scott Stents who wrote (3453)8/3/1998 11:52:00 PM
From: Rick  Read Replies (1) | Respond to of 13953
 
Scott -

Who exactly would buy the "infinite amount of shares" ?

Perhaps E*Trade would enter the biotechnology fray by first issuing an infinite amount of humans. Once they do that, they can issue and distribute an infinite amount of dollars. Then finally, they can hit the road and try to convince everybody to put their infinite amount of money into EGRP.

I think you may be on to something....

Rick.